Aprea Therapeutics, Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 3805 OLD EASTON ROAD, DOYLESTOWN, PA, 18902
Mailing Address 3805 OLD EASTON ROAD, DOYLESTOWN, PA, 18902
Phone 215-948-4119
Fiscal Year End 1231
EIN 000000000
Financial Overview
FY2024
-$12.96M
Net Income
$23.98M
Total Assets
$25.64M
Stockholders' Equity
$22.85M
Cash & Equivalents
$-2.35
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | February 13, 2026 | View on SEC |
| 4 Insider stock transaction report | February 2, 2026 | View on SEC |
| 4 Insider stock transaction report | February 2, 2026 | View on SEC |
| 8-K Current report of material events | January 29, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | January 28, 2026 | View on SEC |
| 8-K Current report of material events | January 23, 2026 | View on SEC |
| 8-K Current report of material events | January 9, 2026 | View on SEC |
| S-3 Shelf registration for future offerings | December 19, 2025 | View on SEC |
| 4 Insider stock transaction report | December 11, 2025 | View on SEC |
| 4 Insider stock transaction report | December 11, 2025 | View on SEC |
Material Events
8-K Financial Distress January 23, 2026
High Impact
- Eprenetapopt Phase 3 trial successfully met its primary goal (complete remission rate) in Myelodysplastic Syndromes (MDS).
- Meeting the primary goal validates the drug's mechanism of action and initial effectiveness, keeping the commercialization pathway open.
Insider Trading
BUY 3 insiders
4 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.